SHANGHAI, Aug. 24,
2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD)
("Zhongchao" or the "Company"), a platform-based internet
technology company offering services for patients with cancer and
other major diseases, today announced it has achieved a milestone
of serving over 10,000 breast cancer patients in China with comprehensive disease management
services since 2021. By offering disease management services,
Zhongchao aims to ensure effective medical treatments while
reducing financial hardships and enhance the overall quality of
life for these patients.
Recently published statistics indicated a great need for disease
management for breast cancer patients in China. The 2022 China Breast Cancer Follow-up
and Health Management Guidelines highlighted the number of
approximately 420,000 new breast cancer diagnoses in China in 2022, which ranked first and
represented almost 20% of all malignant tumors diagnosed in women
in China. As cure rates of breast
cancer increased and the average survival time for is prolonged,
there is an evident rising demand for life-long comprehensive
disease management. Additionally, financial challenges arising from
breast cancer treatment further called for such disease management.
The 2022 China Breast Cancer Patient Quality of Life White Paper
sheds light on the economic strains: breast cancer patients are
burdened with an average treatment expense of RMB206,000, with out-of-pocket costs reaching up
to RBM111,000 based on the questionnaires completed by breast
cancer patients. Particularly, over 64% of these patients had
households income of less than RBM100,000.
Zhongchao initiated its disease management services back in 2021
to alleviate financial burdens and facilitate treatment process for
eligible breast cancer patients. In collaboration with multiple
hospitals, pharmacies, pharmaceutical enterprises, non-profit
organizations and insurance companies, Zhongchao provides various
management services, including but not limited to, drug aids,
disease follow-up visits, medication management, and cancer
education. The Company's dedicated service team, accessible via a
dedicated hotline, offers patient inquiries, medication assistance,
medication usage and experience tracking, and sustained follow-up
visits and management. From 2021 to 2023, Zhongchao's concerted
efforts have aided over 10,000 breast cancer patients. Zhongchao
believes its comprehensive disease management services for breast
cancer patients alleviates financial burdens, promotes patient
education and engagement, and contributes to optimal treatment
results and life quality.
Weiguang Yang, Chairman and Chief
Executive Officer of Zhongchao, commented, "In our position as a
digital platform in healthcare and patient services, we have
consistently prioritized holistic patient support, from financial
assistance to intensive disease management. From 2021, we have
consistently expanded our services to serve more types of cancer
treatment, promoting treatment process, and improving patient
quality of life. Our unwavering dedication to assisting and
supporting breast cancer patients and other major diseases patients
in China remains at the forefront
of our mission."
About Zhongchao Inc.
Zhongchao Inc. is an offshore holding company incorporated in
the Cayman Islands. It
consolidates the financial results of a variable interest entity,
Zhongchao Medical Technology (Shanghai) Limited, and its subsidiaries (the
"PRC operating entities") through a series of contractual
arrangements. Zhongchao Inc. is a platform-based internet
technology company offering services to patients with oncology and
other major diseases. The PRC operating entities provide online
healthcare information, professional training and educational
services to healthcare professionals under their "MDMOOC" platform
(www.mdmooc.org), offer patient management services in the
professional field of tumor and rare diseases through Zhongxin,
offer internet healthcare services through Zhixun Internet
Hospital, and pharmaceutical services through Xinjiang Medical and
operate an online information platform, Sunshine Health Forums, to
general public. More information about the Company can be found at
its investor relations website
at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may," "will," "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
following: the Company's goals and strategies; the Company's future
business development; product and service demand and acceptance;
changes in technology; economic conditions; the growth of the
professional training and educational services market in
China and the other international
markets the Company plans to serve; reputation and brand; the
impact of competition and pricing; government regulations;
fluctuations in general economic and business conditions in
China and the international
markets the Company plans to serve and assumptions underlying or
related to any of the foregoing and other risks contained in
reports filed by the Company with the SEC, the length and severity
of the recent coronavirus outbreak, including its impacts across
our business and operations. For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, which
are available for review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward–looking statements to
reflect events or circumstances that arise after the date
hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 13901629242
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:https://www.prnewswire.com/news-releases/zhongchao-inc-announces-serving-over-10-000-breast-cancer-patients-with-its-comprehensive-disease-management-301908530.html
SOURCE Zhongchao Inc.